Hiroshi Fukui

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8058580/publications.pdf

Version: 2024-02-01

87 papers

8,308 citations

28 h-index 72 g-index

88 all docs 88 docs citations

88 times ranked 14169 citing authors

#	Article	IF	Citations
1	Changes of Intestinal Functions in Liver Cirrhosis. Inflammatory Intestinal Diseases, 2016, 1, 24-40.	0.8	4,709
2	Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology, $2001,34,745$ - $750.$	3.6	346
3	Evidence-based clinical practice guidelines for liver cirrhosis 2015. Journal of Gastroenterology, 2016, 51, 629-650.	2.3	253
4	Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation?. Inflammatory Intestinal Diseases, 2016 , 1 , $135-145$.	0.8	247
5	Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology, 2000, 32, 1248-1254.	3.6	233
6	Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology, 1992, 16, 358-364.	3.6	228
7	The Effect of Inflammatory Cytokines in Alcoholic Liver Disease. Mediators of Inflammation, 2013, 2013, 1-10.	1.4	183
8	Plasma Endotoxin and Serum Cytokine Levels in Patients With Alcoholic Hepatitis: Relation to Severity of Liver Disturbance. Alcoholism: Clinical and Experimental Research, 2000, 24, 48S.	1.4	157
9	The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. International Journal of Cancer, 2001, 94, 768-773.	2.3	145
10	Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. World Journal of Hepatology, 2015, 7, 425.	0.8	141
11	Vascular endothelial growth factor tightly regulatesin vivo development of murine hepatocellular carcinoma cells. Hepatology, 1998, 28, 1489-1496.	3.6	97
12	KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology, 1999, 30, 1179-1186.	3.6	90
13	Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?. Diseases (Basel, Switzerland), 2019, 7, 58.	1.0	84
14	Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma. Hepatology, 1995, 22, 1838-1846.	3.6	76
15	Relation of Endotoxin, Endotoxin Binding Proteins and Macrophages to Severe Alcoholic Liver Injury and Multiple Organ Failure. Alcoholism: Clinical and Experimental Research, 2005, 29, 172S-179S.	1.4	71
16	Segmental transarterial chemoembolization with lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma: follow-up CT and therapeutic results. Cancer Chemotherapy and Pharmacology, 1994, 33, S60-S68.	1.1	63
17	Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model. Molecular Medicine Reports, 2015, 11, 1693-1700.	1.1	62
18	Effects of glycyrrhizin on immune-mediated cytotoxicity. Journal of Gastroenterology and Hepatology (Australia), 1997, 12, 243-248.	1.4	56

#	Article	IF	CITATIONS
19	Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update. Gut and Liver, 2021, 15, 666-676.	1.4	54
20	The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model. Hepatology, 2001, 33, 841-847.	3 . 6	49
21	Gut Microbiota and Host Reaction in Liver Diseases. Microorganisms, 2015, 3, 759-791.	1.6	47
22	Exacerbation of Ulcerative Colitis during Alpha-Interferon Therapy for Chronic Hepatitis C Internal Medicine, 1993, 32, 327-331.	0.3	43
23	Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step. Journal of Clinical and Translational Hepatology, 2017, 5, 249-260.	0.7	41
24	Differential Expression of Drug Uptake and Efflux Transporters in Japanese Patients with Hepatocellular Carcinoma. Drug Metabolism and Disposition, 2014, 42, 2033-2040.	1.7	38
25	Cysteinyl leukotrienes in the urine of patients with liver diseases. Hepatology, 1994, 20, 804-812.	3.6	37
26	Cytosine deaminase/5-fluorocytosine gene therapy can induce efficient anti-tumor effects and protective immunity in immunocompetent mice but not in athymic nude mice., 1999, 81, 592-597.		36
27	Endotoxin clearance and its relation to hepatic and renal disturbances in rats with liver cirrhosis. Liver, 2001, 21, 64-70.	0.1	32
28	Hepatocellular carcinoma in an orthotopic mouse model metastasizes intrahepatically in cirrhotic but not in normal liver., 1999, 80, 471-476.		30
29	Predictive parameter of tolvaptan effectiveness in cirrhotic ascites. Hepatology Research, 2017, 47, 854-861.	1.8	30
30	Role of Albumin and High-Density Lipoprotein as Endotoxin-Binding Proteins in Rats with Acute and Chronic Alcohol Loading. Alcoholism: Clinical and Experimental Research, 1996, 20, 73a-76a.	1.4	28
31	von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C. United European Gastroenterology Journal, 2018, 6, 1401-1409.	1.6	27
32	Tissue-specific expression of HSV-tk gene can induce efficient antitumor effect and protective immunity to wild-type hepatocellular carcinoma., 1997, 71, 470-475.		26
33	Treatment for cirrhotic ascites. Hepatology Research, 2017, 47, 166-177.	1.8	24
34	Effect of Treatment with Paromomycin on Endotoxemia in Patients with Alcoholic Liver Disease-A Double-Blind, Placebo-Controlled Trial. Alcoholism: Clinical and Experimental Research, 1997, 21, 1367-1373.	1.4	23
35	Prognostic Factors in Severe Alcoholic Liver Injury. Alcoholism: Clinical and Experimental Research, 1999, 23, 33S-38S.	1.4	23
36	Analysis of the KAL1 Gene in 19 Japanese Patients with Kallmann Syndrome Endocrine Journal, 2001, 48, 143-149.	0.7	23

#	Article	IF	Citations
37	Decreased activity of plasma ADAMTS13 are related to enhanced cytokinemia and endotoxemia in patients with acute liver failure. Biomedical Reports, 2017, 7, 277-285.	0.9	23
38	Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology, $2001, 34, 745-750$.	3.6	22
39	Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites?. World Journal of Gastroenterology, 2015, 21, 11584.	1.4	22
40	Endotoxin inactivating action of plasma in patients with liver cirrhosis. Liver, 1995, 15, 104-109.	0.1	21
41	Immunomodulation with FK506 around the time of intravenous re-administration of an adenoviral vector facilitates gene transfer into primed rat liver. , 2000, 85, 839-844.		20
42	Electrochemotherapy for colorectal cancer with commonly used chemotherapeutic agents in a mouse model. Digestive Diseases and Sciences, 2000, 45, 1568-1577.	1.1	20
43	Promoting effect of citrulline in hepatocarconogenesis: Possbile mechanism in hypercitrullinemia. Hepatology, 1990, 11, 819-823.	3.6	19
44	Comparison of carcinoembryonic antigen promoter regions isolated from human colorectal carcinoma and normal adjacent mucosa to induce strong tumor-selective gene expression., 1998, 78, 242-247.		19
45	Microscopic polyangiitis complicated with massive intestinal bleeding. Journal of Gastroenterology, 2001, 36, 264-270.	2.3	18
46	Management of refractory cirrhotic ascites: challenges and solutions. Hepatic Medicine: Evidence and Research, 2018, Volume 10, 55-71.	0.9	18
47	Endotoxaemia in patients with liver cirrhosis and upper gastrointestinal bleeding: Detection by the chromogenic assay with plasma Tween 80 pretreatment. Journal of Gastroenterology and Hepatology (Australia), 1993, 8, 577-581.	1.4	17
48	Hepatic adenomas treated with percutaneous ethanol injection in a patient with glycogen storage disease type Ia. Journal of Gastroenterology, 2001, 36, 52-61.	2.3	17
49	CASE OF HEMORRHAGE FROM A DUODENAL DIVERTICULUM TREATED SUCCESSFULLY BY ENDOSCOPIC INJECTIONS OF EPINEPHRINE. Digestive Endoscopy, 2001, 13, 27-32.	1.3	17
50	Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis. International Journal of Molecular Sciences, 2021, 22, 6921.	1.8	16
51	A Novel Mutation of the KAL1 Gene in Kallmann Syndrome Endocrine Journal, 1999, 46, 651-658.	0.7	14
52	Chronic Active Epstein-Barr Virus Infection in an Adult Internal Medicine, 1992, 31, 1190-1196.	0.3	13
53	Interaction of Kupffer cells to splenic macrophages and hepatocytes in endotoxin clearance: Effect of alcohol. Journal of Gastroenterology and Hepatology (Australia), 1995, 10, S31-S34.	1.4	12
54	Interferon treatment of chronic hepatitis C in patients with hemophilia or von Willebrand's disease in Japan. Journal of Gastroenterology, 1995, 30, 367-371.	2.3	12

#	Article	IF	CITATIONS
55	Plasma endotoxin concentration and endotoxin binding capacity of plasma acute phase proteins in cirrhotics with variceal bleeding: An analysis by new methods. Journal of Gastroenterology and Hepatology (Australia), 1994, 9, 582-586.	1.4	11
56	Immunological Adverse Effects of Interferon Treatment. BioDrugs, 1995, 4, 361-375.	0.7	10
57	Stepped care medical treatment for cirrhotic ascites: Analysis of factors influencing the response to treatment. Journal of Gastroenterology and Hepatology (Australia), 1995, 10, 30-35.	1.4	10
58	Acute hepatic failure due to hepatosplenic B-cell non-Hodgkin's lymphoma in a patient infected with hepatitis C virus. Journal of Gastroenterology, 1998, 33, 880-885.	2.3	10
59	Platelet hyperaggregability is associated with decreased ADAMTS13 activity and enhanced endotoxemia in patients with acute cholangitis. Hepatology Research, 2018, 48, E52-E60.	1.8	10
60	Disappearance of serum HCV-RNA after short-term prednisolone therapy in a patient with chronic hepatitis C associated with autoimmune hepatitis-like serological manifestations. Journal of Gastroenterology, 1999, 34, 269-274.	2.3	9
61	Microscopic Polyangiitis That Presented Liver Dysfunction Prior to Noted Renal Manifestations Internal Medicine, 2000, 39, 517-521.	0.3	9
62	Risk factors for the development of gastric mucosal lesions in rheumatoid arthritis patients receiving long-term nonsteroidal anti-inflammatory drug therapy and the efficacy of famotidine obtained from the FORCE study. Modern Rheumatology, 2009, 19, 629-636.	0.9	9
63	48,XXYY Syndrome Associated with Acromegaloidism Internal Medicine, 1993, 32, 160-165.	0.3	8
64	Effects of "body compression" on parameters related to ascites formation: therapeutic trial in cirrhotic patients. Journal of Gastroenterology, 1999, 34, 75-82.	2.3	6
65	Improve gut microbiome: a new horizon of cancer therapy. Hepatobiliary Surgery and Nutrition, 2017, 6, 424-428.	0.7	6
66	Protective Mechanism of High-Density Lipoprotein against Endotoxemia in Chronic Alcohol Ingestion. Alcoholism: Clinical and Experimental Research, 1996, 20, 356A-359A.	1.4	5
67	Secondary aortoduodenal fistula identified by ultrasonography. Journal of Medical Ultrasonics (2001), 2011, 38, 161-165.	0.6	5
68	Cerebral Hemorrhage in Turner Syndrome: A Case Report. Clinical Pediatric Endocrinology, 2005, 14, 35-37.	0.4	5
69	Plasma levels of atrial natriuretic peptide in patients with liver cirrhosis and its relation to ascites and renal function. Gastroenterologia Japonica, 1989, 24, 149-155.	0.4	4
70	Severe toxicity of chemotherapy against advanced soft tissue sarcoma in Werner's syndrome: Ifosfamide-induced encephalopathy with central diabetes insipidus. Journal of Orthopaedic Science, 2016, 21, 403-406.	0.5	4
71	Radical esophagogastrectomy for unshuntable extrahepatic portal hypertension with bleeding varices: Report of a case. Surgery Today, 1997, 27, 243-246.	0.7	3
72	Effect of Alcohol on the Secretion of Tumor Necrosis Factor-alpha by Macrophages in the Presence of Rat Serum. Alcoholism: Clinical and Experimental Research, 2002, 26, 81s-85s.	1.4	3

#	Article	IF	Citations
73	A case of early gastric malignant lymphoma diagnosed and completely resected by strip biopsy. Journal of Gastroenterology, 1995, 30, 248-253.	2.3	2
74	Effect of Prostaglandin E Receptor Subtype EP4 Selective Agonist on the Secretion of Tumor Necrosis Factor-alpha by Macrophages in Acute Ethanol-Loaded Rats. Alcoholism: Clinical and Experimental Research, 2004, 28, 123S-128S.	1.4	2
75	A new link between innate immunity and hepatic metabolism: attractive unknown place to visit. Hepatobiliary Surgery and Nutrition, 2017, 6, 264-267.	0.7	2
76	Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. Experimental and Therapeutic Medicine, 2020, 21, 1-1.	0.8	2
77	Potential Role of Enhanced Cytokinemia and Endotoxemia on the Decreased Activity of Plasma ADAMTS13 in Patients with Alcoholic Hepatitis Blood, 2008, 112, 2292-2292.	0.6	1
78	Imported <i>Plasmodium malariae</i> Malaria. Internal Medicine, 1993, 32, 355-355.	0.3	0
79	Variant Type of Congenital Stomatocytosis Internal Medicine, 1994, 33, 103-106.	0.3	0
80	Difficulty in evaluating intestinal permeability in patients with liver cirrhosis: What is the precipitating factor?. Hepatology Research, 2013, 43, 179-181.	1.8	0
81	Plasma ADAMTS13 Activity Markedly Decreases in Patients with Severe Acute Pancreatitis: Its Potential Role on the Development of Multiorgan Failure Blood, 2007, 110, 2160-2160.	0.6	0
82	Decreased Activity of Plasma ADAMTS13 Parallels Enhanced Endotoxemia in Patients with Severe Acute Pancreatitis: Relationship to Multiorgan Failure. Blood, 2008, 112, 4541-4541.	0.6	0
83	Quality of ambulatory care provided by physicians-in-training for common diseases before and after the Japanese government reformed post-graduate medical education. Tenri Medical Bulletin, 2012, 15, 25-33.	0.1	0
84	Factor VIII procoagulant activity (VIII: C), factor VIII related antigen (VIII R: AG), and von Willebrand factor (VIII R: wF) in newborn cord blood and in pregnant maternal blood. Blood & Vessel, 1979, 10, 346-349.	0.0	0
85	A case of imported Plasmodium malariae malaria Tropical Medicine and Health, 1993, 21, 127-130.	0.1	0
86	Successful Hemostatic Management of Dieulafoy's Ulcer in Two Patients with Hemophilia A with Inhibitor. Japanese Journal of Thrombosis and Hemostasis, 1995, 6, 15-21.	0.1	0
87	Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. Experimental and Therapeutic Medicine, 2021, 21, 30.	0.8	0